Sulfonamide substituted chroman derivatives useful as beta 3 adr

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514340, 514343, 514382, 514456, 5462684, 5462831, 5462764, 548251, 549399, 549404, C07D31158, C07D40512, C07D40712, A61K 31353

Patent

active

060515864

ABSTRACT:
This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.

REFERENCES:
patent: 3706764 (1972-12-01), Nakanishi et al.
patent: 3803176 (1974-04-01), Christensen et al.
patent: 4647579 (1987-03-01), Kabbe et al.
patent: 4650812 (1987-03-01), Cohen et al.
patent: 4654362 (1987-03-01), Van Lommen et al.
patent: 5393775 (1995-02-01), Le Baut et al.
patent: 5451677 (1995-09-01), Fisher et al.
patent: 5516917 (1996-05-01), Djuric et al.
patent: 5541197 (1996-07-01), Fisher et al.
patent: 5561142 (1996-10-01), Fisher et al.
patent: 5663194 (1997-09-01), Mewshaw
Silverman, Structure modifications to increase potency and Therapeutic Index, The Organic Chemistry of Drug Design and Drug Action, pp. 15-22, 1992.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Sulfonamide substituted chroman derivatives useful as beta 3 adr does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonamide substituted chroman derivatives useful as beta 3 adr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide substituted chroman derivatives useful as beta 3 adr will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2336642

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.